LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma

References

• Kelly KM, Hodgson D, Appel B, et al. COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2013;60(6):972–978.
   PubMed Web of Science ®Google Scholar
• Baker KS, Gordon BG, Gross TG, et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol. 1999;17(3):825–831.
   PubMed Web of Science ®Google Scholar
• Shankar A, Hayward J, Kirkwood A, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma–results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165(4):534–544.
   PubMed Web of Science ®Google Scholar
• Cole PD, McCarten KM, Pei Q, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial. Lancet Oncol. 2018;19(9):1229–1238.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–48.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma. Br J Haematol. 2020;189(3):e86–e90.
   PubMed Web of Science ®Google Scholar
• Perales M-A, Ceberio I, Armand P, American Society for Blood and Marrow Transplantation, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2015;21(6):971–983.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Marciscano AE, Drake CG, et al. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276(1):80–96.
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690–2697.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, KEYNOTE-087, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020;21(1):121–133.
   PubMed Web of Science ®Google Scholar
• Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020;21(4):541–550.
   PubMed Web of Science ®Google Scholar
• Long L, Zhang X, Chen F, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5–6):176–189.
   PubMedGoogle Scholar
• Baixeras E, Huard B, Miossec C, et al. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176(2):327–337.
   PubMed Web of Science ®Google Scholar
• Huard B, Prigent P, Tournier M, et al. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995;25(9):2718–2721.
   PubMed Web of Science ®Google Scholar
• Saleh RR, Peinado P, Fuentes-Antras J, et al. Prognostic value of lymphocyte-activation gene 3 (LAG3) in cancer: a meta-analysis. Front Oncol. 2019;9:1040.
   PubMed Web of Science ®Google Scholar
• Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J *Clin Oncol. 2014;32(32):3651–3658.
   PubMed Web of Science ®Google Scholar
• Moerdler SC, Ewart M, Zang X, et al. HHLA2 is a New Immune Checkpoint Expressed in Pediatric Hodgkin Lymphoma. AACR Advances in Pediatric Cancer Research Conference September 2019, Montreal, Canada, 2019.
   Google Scholar
• Janakiram M, Chinai JM, Fineberg S, et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin Cancer Res. 2015;21(10):2359–2366.
   PubMed Web of Science ®Google Scholar
• Chen BJ, Dashnamoorthy R, Galera P, et al. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. Oncotarget. 2019;10(21):2030–2040.
   PubMedGoogle Scholar
• Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood J Am Soc Hematol. 2020;135(8):523–533.
   Google Scholar
• Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon (France): International Agency for Research on Cancer; 2017.
   Google Scholar
• Karyampudi L, Lamichhane P, Krempski J, et al. PD-1 blunts the function of ovarian tumor-infiltrating dendritic cells by inactivating NF-κB. Cancer Res. 2016;76(2):239–250.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res. 2005;11(4):1467–1473.
   PubMed Web of Science ®Google Scholar
• Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182:207–214.
   PubMed Web of Science ®Google Scholar
• Taube JM, Young GD, McMiller TL, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21(17):3969–3976.
   PubMed Web of Science ®Google Scholar
• Gros A, Robbins PF, Yao X, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124(5):2246–2259.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xiang Y, Ding L, et al. Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia. BMC Bioinformatics. 2010;11 (Suppl 9):S5.
   PubMed Web of Science ®Google Scholar
• Datar I, Sanmamed MF, Wang J, et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis. Clin Cancer Res. 2019;25(15):4663–4673.
   PubMed Web of Science ®Google Scholar
• Hald SM, Rakaee M, Martinez I, et al. LAG-3 in non-small-cell lung cancer: expression in primary tumors and metastatic lymph nodes is associated with improved survival. Clin Lung Cancer. 2018;19(3):249–259.e2.
   PubMed Web of Science ®Google Scholar
• Que Y, Fang Z, Guan Y, et al. LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival. Cancer Biol Med. 2019;16(2):331–340.
   PubMed Web of Science ®Google Scholar
• Sun N, Li Y, He J. Clinical relevance of common inhibitory immune checkpoint genes in esophageal squamous cell carcinoma. Zhonghua Yi Xue Za Zhi. 2018;98(21):1703–1706.
   PubMedGoogle Scholar
• Wang W, Chen D, Zhao Y, et al. Characterization of LAG-3, CTLA-4, and CD8(+) TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma. Ann Transl Med. 2019;7(23):776.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu YD, Luo YL, et al. Prognostic value of lymphocyte activation gene-3 (LAG-3) expression in esophageal squamous cell carcinoma. J Cancer. 2018;9(22):4287–4293.
   PubMed Web of Science ®Google Scholar
• el Halabi L, Adam J, Marty V, et al. Strong expression of the immune checkpoint regulators LAG3 and Tim3 in Hodgkin lymphoma. Washington (DC): American Society of Hematology; 2016.
   Google Scholar
• Patel SS, Weirather JL, Lipschitz M, et al. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Blood. 2019;134(23):2059–2069.
   PubMed Web of Science ®Google Scholar
• Metzger ML, Mauz-Korholz C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. Br J Haematol. 2019;185(6):1142–1157.
   PubMed Web of Science ®Google Scholar
• Fumet JD, Richard C, Ledys F, et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer. 2018;119(8):950–960.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautes-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Redd RA, et al. Classical Hodgkin lymphoma with reduced β2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol Res. 2016;4(11):910–916.
   PubMed Web of Science ®Google Scholar
• D'Haene N, Maris C, Sandras F, et al. The differential expression of Galectin-1 and Galectin-3 in normal lymphoid tissue and non-Hodgkin's and Hodgkin's lymphomas. Int J Immunopathol Pharmacol. 2005;18(3):431–443.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Melero I, Bhatia S, et al. Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. Washington, DC: American Society of Clinical Oncology; 2017.
   Google Scholar
• Ascierto PA, Bono P, Bhatia S, et al. LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Ann Oncol. 2017;28(Suppl_5):v611–v612.
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Amin A, Kovacs C, et al. A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies. Am Soc Clin Oncol. 2018;36(Suppl_15):TPS2616.
   PubMed Web of Science ®Google Scholar
• Haines BB, Javaid S, Cui L, et al. Abstract nr 4714: Blockade of LAG-3 amplifies immune activation signatures and augments curative antitumor responses to anti-PD-1 therapy in immune competent mouse models of cancer. AACR Annual Meeting 2017; 2017.
   Google Scholar
• Ghosh S, Sharma G, Travers J, et al. TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo. Mol Cancer Ther. 2019;18(3):632–641.
   PubMed Web of Science ®Google Scholar
• Savitsky D, Ward R, Riordan C, et al. Abstract nr 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies. AACR; 2018.
   Google Scholar
• Bjoern J, Lyngaa R, Andersen R, et al. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. Oncotarget. 2017;8(16):27062–27074.
   PubMedGoogle Scholar